Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Oral pharmaceutical composition for treating ventricular remodeling after myocardial infarction

A technology for ventricular remodeling and myocardial infarction, applied in the field of medicine, can solve the problems of lack of targeted therapeutic drugs and unclear mechanism

Inactive Publication Date: 2018-06-26
姚蕾
View PDF7 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] In summary, the mechanism of ventricular remodeling after myocardial infarction is still unclear, and there is a lack of targeted therapeutic drugs in clinical practice.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Oral pharmaceutical composition for treating ventricular remodeling after myocardial infarction
  • Oral pharmaceutical composition for treating ventricular remodeling after myocardial infarction
  • Oral pharmaceutical composition for treating ventricular remodeling after myocardial infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0028] Example 1 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0029]

[0030] Preparation:

[0031] A: Take atorvastatin, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0032] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0033] The amount is 2.2 times the weight of atorvastatin; the amount of microcrystalline cellulose is 1.2 times the weight of atorvastatin; the amount of crospovidone is 0.13 times the weight of atorvastatin.

[0034] C: Mix the powder obtained in step A and step B evenly.

[0035] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of atorvastatin; the consumption of water is 32.5 times of the weight of povidone K30.

[0036] E: The liquid dispersion system obtained in ste...

Embodiment 2

[0038] Example 2 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0039]

[0040] Preparation:

[0041] A: Take atorvastatin, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0042] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0043] The amount is 2.2 times the weight of atorvastatin; the amount of microcrystalline cellulose is 1.2 times the weight of atorvastatin; the amount of crospovidone is 0.13 times the weight of atorvastatin.

[0044] C: Mix the powder obtained in step A and step B evenly.

[0045] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of atorvastatin; the consumption of water is 32.5 times of the weight of povidone K30.

[0046] E: The liquid dispersion system obtained in ste...

Embodiment 3

[0048] Example 3 Granules for treating ventricular remodeling after myocardial infarction and its preparation

[0049]

[0050] Preparation:

[0051] A: Take atorvastatin, disulfiram, primaquine, and rorapitant and pass through a 100-mesh sieve, and mix well.

[0052] B: Take lactose, microcrystalline cellulose, and crospovidone to pass through a 100-mesh sieve, and mix well. where lactose is used

[0053] The amount is 2.2 times the weight of atorvastatin; the amount of microcrystalline cellulose is 1.2 times the weight of atorvastatin; the amount of crospovidone is 0.13 times the weight of atorvastatin.

[0054] C: Mix the powder obtained in step A and step B evenly.

[0055] D: Take povidone K30 and add water and stir well to make a liquid dispersion system. Wherein the consumption of povidone K30 is 0.18 times of the weight of atorvastatin; the consumption of water is 32.5 times of the weight of povidone K30.

[0056] E: The liquid dispersion system obtained in ste...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the field of medicine, and particularly relates to an oral drug composition for treating ventricular remodeling after myocardial infarction. The oral drug composition for treating ventricular remodeling after myocardial infarction is prepared from pharmaceutically acceptable adjuvants in medical science and the following components in parts by weight: 53-97 parts of atorvastatin, 8-14 parts of disulfiram, 5-11 parts of neoquipenyl, and 3-7 parts of rolapitant. In the composition, rolapitant can inhibit the cardiovascular toxic effect of disulfiram and neoquipenyl, andcan eliminate the phenomenon that the efficacies of disulfiram and neoquipenyl counteract when being combined in use. The formula of atorvastatin, disulfiram, neoquipenyl and rolapitant has good effects and safety for resisting ventricular remodeling after myocardial infarction.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to an oral pharmaceutical composition for treating ventricular remodeling after myocardial infarction. Background technique [0002] Ventricular remodeling after myocardial infarction refers to the structural and morphological changes of the infarcted area and non-infarcted area of ​​the ventricle after myocardial infarction. Its typical manifestation is ventricular decompensated hypertrophy; ventricular weight, volume increase and shape change can cause ventricular pump function hypofunction and develop into heart failure. The basic mechanism leading to the development of heart failure is ventricular remodeling. This symptom is a persistent and progressive change following myocardial infarction, and its severity determines the patient's cardiac function and prognosis. With the increase in the incidence of myocardial infarction, ventricular remodeling after myocardial infarctio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/438A61K31/40A61K31/145A61K31/4706A61K9/16A61P9/10A61P9/04
CPCA61K9/1635A61K9/1652A61K31/145A61K31/40A61K31/438A61K31/4706A61K2300/00
Inventor 孙振秋侯瑞玲王全政姚蕾张玉清
Owner 姚蕾
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com